Results for tag: "Replagal"

Replagal is a central nervous system drug used to treat Fabry disease, a rare genetic disorder. It is a recombinant form of the human enzyme alpha-galactosidase A, which is deficient in patients with Fabry disease. Replagal is administered as an intravenous infusion and works by breaking down a fatty substance called globotriaosylceramide (Gb3) that accumulates in the cells of patients with Fabry disease. This helps to reduce the symptoms of the disease, such as pain, tingling, and burning sensations in the hands and feet. Replagal is marketed by Shire, a biopharmaceutical company based in Ireland. Other companies in the market include Amicus Therapeutics, a biopharmaceutical company based in the United States, and Sanofi, a French multinational pharmaceutical company. Show Less Read more